BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more
BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Total Assets
Latest total assets as of September 2025: ₹3.22 Billion INR
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) holds total assets worth ₹3.22 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BALAXI PHARMACEUTICALS LIMITED - Total Assets Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BALAXI PHARMACEUTICALS LIMITED - Asset Composition Analysis
Current Asset Composition (March 2025)
BALAXI PHARMACEUTICALS LIMITED's total assets of ₹3.22 Billion consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 12.7% |
| Accounts Receivable | ₹1.11 Billion | 35.7% |
| Inventory | ₹784.81 Million | 25.3% |
| Property, Plant & Equipment | ₹363.11 Million | 11.7% |
| Intangible Assets | ₹6.61 Million | 0.2% |
| Goodwill | ₹267.45 Million | 8.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BALAXI PHARMACEUTICALS LIMITED's current assets represent 78.2% of total assets in 2025, an increase from 62.1% in 2013.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2025, down from 42.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 35.7% of total assets.
BALAXI PHARMACEUTICALS LIMITED Competitors by Total Assets
Key competitors of BALAXI PHARMACEUTICALS LIMITED based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BALAXI PHARMACEUTICALS LIMITED - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - BALAXI PHARMACEUTICALS LIMITED generates 0.93x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, BALAXI PHARMACEUTICALS LIMITED generates $8.08 in net profit.
BALAXI PHARMACEUTICALS LIMITED - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.96 | 3.45 | 2.33 |
| Quick Ratio | 2.66 | 2.22 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹1.78 Billion | ₹ 1.70 Billion | ₹ 413.15 Million |
BALAXI PHARMACEUTICALS LIMITED - Advanced Valuation Insights
This section examines the relationship between BALAXI PHARMACEUTICALS LIMITED's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 20.1% |
| Total Assets | ₹3.10 Billion |
| Market Capitalization | $10.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values BALAXI PHARMACEUTICALS LIMITED's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BALAXI PHARMACEUTICALS LIMITED's assets grew by 20.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual total assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹3.10 Billion | +20.13% |
| 2024-03-31 | ₹2.58 Billion | +7.79% |
| 2023-03-31 | ₹2.40 Billion | +35.81% |
| 2022-03-31 | ₹1.76 Billion | +77.04% |
| 2021-03-31 | ₹996.80 Million | +177.11% |
| 2020-03-31 | ₹359.71 Million | +488.93% |
| 2019-03-31 | ₹61.08 Million | +262.13% |
| 2018-03-31 | ₹16.87 Million | -34.54% |
| 2017-03-31 | ₹25.77 Million | +7117.47% |
| 2016-03-31 | ₹356.99K | -3.02% |
| 2015-03-31 | ₹368.10K | -96.94% |
| 2014-03-31 | ₹12.04 Million | -2.76% |
| 2013-03-31 | ₹12.38 Million | -- |